JAK inhibition decreases the autoimmune burden in Down syndrome

- Author list: Angela L. Rachubinski^{1,2*}, Elizabeth Wallace³, Emily Gurnee³, Belinda A. Enriquez
- 3 Estrada¹, Kayleigh R. Worek¹, Keith P. Smith¹, Paula Araya¹, Katherine A. Waugh^{1,4}, Ross E.
- 4 Granrath¹, Eleanor Britton¹, Hannah R. Lyford¹, Micah G. Donovan^{1,5}, Neetha Paul Eduthan¹, Amanda
- 5 A. Hill¹, Barry Martin⁶, Kelly D. Sullivan^{1,7}, Lina Patel^{1,8}, Deborah J. Fidler⁹, Matthew D. Galbraith^{1,5},
- 6 Cory A. Dunnick³, David A. Norris³, Joaquin M. Espinosa^{1,5*}.

7 Affiliations:

- 8 ¹Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora,
- 9 CO, USA.
- ²Department of Pediatrics, Section of Developmental Pediatrics, University of Colorado Anschutz
- 11 Medical Campus, Aurora, CO, USA.
- ³Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- ⁴Current address: Department of Cell Biology and Physiology, University of Kansas Medical Center,
- 14 Kansas City, KS, USA.
- ⁵Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- ⁶Department of Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO,
- 17 USA.
- ⁷Department of Pediatrics, Section of Developmental Biology, University of Colorado Anschutz
- 19 Medical Campus, Aurora, CO, USA.
- ⁸Department of Psychiatry, Child and Adolescent Division, University of Colorado Anschutz Medical
- 21 Campus, Aurora, CO, USA.
- ⁹Department of Human Development and Family Studies, Colorado State University, Fort Collins, CO.
- 23 USA.

24 *Corresponding authors:

26

joaquin.espinosa@cuanschutz.edu/angela.rachubinski@cuanschutz.edu

Abstract.

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Individuals with Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), display clear signs of immune dysregulation, including high rates of autoimmune disorders and severe complications from infections. Although it is well established that T21 causes increased interferon responses and JAK/STAT signaling, elevated autoantibodies, global immune remodeling, and hypercytokinemia, the interplay between these processes, the clinical manifestations of DS, and potential therapeutic interventions remain ill defined. Here, we report a comprehensive analysis of immune dysregulation at the clinical, cellular, and molecular level in hundreds of individuals with DS. We demonstrate multi-organ autoimmunity of pediatric onset concurrent with unexpected autoantibody-phenotype associations. Importantly, constitutive immune remodeling and hypercytokinemia occur from an early age prior to autoimmune diagnoses or autoantibody production. We then report the interim analysis of a Phase II clinical trial investigating the safety and efficacy of the JAK inhibitor tofacitinib through multiple clinical and molecular endpoints. Analysis of the first 10 participants to complete the 16-week study shows a good safety profile and no serious adverse events. Treatment reduced skin pathology in alopecia areata, psoriasis, and atopic dermatitis, while decreasing interferon scores, cytokine scores, and levels of pathogenic autoantibodies without overt immune suppression. Additional research is needed to define the effects of JAK inhibition on the broader developmental and clinical hallmarks of DS. ClinicalTrials.gov identifier: NCT04246372.

Introduction.

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Trisomy of human chromosome 21 (T21) occurs at a rate of ~1 in 700 live births, causing Down syndrome (DS)^{1,2}. Individuals with DS display a distinct clinical profile including developmental delays, stunted growth, cognitive impairments, and increased risk of leukemia, autism spectrum disorders, seizure disorders, and Alzheimer's disease^{2,3}. People with DS also display widespread immune dysregulation, which manifests through severe complications from respiratory viral infections and high prevalence of myriad immune conditions, including autoimmune thyroid disease (AITD)⁴⁻⁶, celiac disease^{7,8}, and skin conditions such as atopic dermatitis, alopecia areata, hidradenitis suppurativa (HS), vitiligo, and psoriasis⁹-¹¹. Furthermore, people with DS display signs of neuroinflammation from an early age¹²⁻¹⁴. Although it is now well accepted that immune dysregulation is a hallmark of DS, the underlying mechanisms and therapeutic implications are not yet fully defined. We previously reported that T21 causes consistent activation of the interferon (IFN) transcriptional response in multiple immune and non-immune cell types with concurrent hypersensitivity to IFN stimulation and hyperactivation of downstream JAK/STAT signaling¹⁵⁻¹⁷. Plasma proteomics studies identified dozens of inflammatory cytokines with mechanistic links to IFN signaling that are elevated in people with DS¹⁸. A large metabolomics study revealed that T21 drives the production of neurotoxic tryptophan catabolites via the IFN-inducible kynurenine pathway¹⁹. Deep immune profiling revealed global immune remodeling with hypersensitivity to IFN across all major branches of the immune system¹⁵, and dysregulation of T cell lineages toward a hyperactive, autoimmunity-prone state 16. These results could be partly explained by the fact that four of the six IFN receptors (IFNRs) are encoded on chr21, including Type I, II and III IFNR subunits²⁰. In a mouse model of DS, normalization of *IFNR* gene copy number rescues multiple phenotypes of DS, including lethal immune hypersensitivity, congenital heart defects (CHDs), cognitive impairments, and craniofacial anomalies²¹. JAK inhibition rescues lethal immune hypersensitivity in these mouse models²² and attenuates the global dysregulation of gene expression caused by the trisomy across multiple murine tissues²³. Furthermore, prenatal JAK inhibition in pregnant mice prevents the appearance of CHDs²⁴. Altogether, these results support the notion that T21 elicits an interferonopathy in DS, and that pharmacological inhibition of IFN signaling could have multiple therapeutic benefits in this population.

Although it is now well established that T21 disrupts immune homeostasis toward an autoimmunity-prone state, the interplay between overexpression of chromosome 21 genes, hyperactive interferon signaling, dysregulation of immune cell lineages, autoantibody production, hypercytokinemia, and the various developmental and clinical features of DS remain to be elucidated. Previous studies established similarities between the immune profiles of typical aging, autoimmunity in the general population, and DS, proposing a role for accelerated immune aging in the pathophysiology of DS²⁵⁻²⁷. Other studies indicate a role for elevated cytokine production, hyperactivated T cells, and ongoing B cell activation as drivers of autoimmunity in DS^{15,16,28}. However, given the relatively small sample sizes and observational nature of these studies, it has not been possible to define the contribution of specific dysregulated events to breach of tolerance leading to clinically evident autoimmunity in DS. Therefore, additional research is needed to define driver versus bystander events that could illuminate therapeutic strategies to decrease the burden of autoimmunity in DS.

Within this context, we report here a comprehensive analysis of the immune disorder of DS, including detailed annotation of autoimmune and inflammatory conditions and quantification of autoantibodies in hundreds of research participants, which reveals widespread autoimmune attack on all major organ systems in DS from an early age, including unexpected autoantibody-phenotype associations. Then, using deep immune mapping and quantitative proteomics, we demonstrate that T21 causes widespread immune remodeling toward an autoimmunity-prone state accompanied by hypercytokinemia prior to clinically evident autoimmunity or autoantibody production. Lastly, we report the interim analysis of a clinical trial investigating the safety and efficacy of the JAK1/3 inhibitor tofacitinib (Xeljanz, Pfizer) in DS. These results demonstrate that JAK inhibition improves multiple immunodermatological conditions in DS, normalizes interferon scores, decreases levels of major pathogenic cytokines (e.g., TNF-α, IL-6), and

- 96 reduces levels of pathogenic autoantibodies [e.g., anti-thyroid peroxidase (anti-TPO)]. Altogether, these
- 97 results point to hyperactive JAK/STAT signaling as driver of autoimmunity in DS and justify the ongoing
- 98 trials of JAK inhibitors in DS for multiple clinical endpoints.

Results.

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

Widespread multi-organ autoimmunity and autoantibody production in Down syndrome.

Previous studies have documented increased rates of diverse autoimmune conditions in DS relative to the general population including autoimmune thyroid disease (AITD)²⁹, celiac disease³⁰, autoimmune skin conditions⁹⁻¹¹, and type I diabetes^{31,32}. However, many of these studies were limited by relatively small sample sizes, independent analysis of individual autoimmune conditions, or a focus on specific age ranges. In order to complete a more comprehensive analysis of autoimmune conditions in DS across the lifespan, we analyzed the harmonized clinical profiles of 441 research participants with DS, aged 6 months to 57 years, enrolled in the Human Trisome Project cohort study (HTP, NCT02864108), which annotates clinical data through a combination of participant/caregiver surveys and expert abstraction of electronic health records (EHRs) (see Materials and Methods, Supplementary file 1). In this analysis, the most common autoimmune condition is AITD, affecting 53.1% of the total cohort (Figure 1a, Figure 1 – figure supplement 1a). Grouped together, autoimmune and inflammatory skin conditions represent the second most common category, affecting 43% of the cohort, including: atopic dermatitis / eczema (27.9%), hidradenitis suppurativa / folliculitis / boils (20.6%), alopecia areata (7.7%), psoriasis (6.1%), and vitiligo (1.9%) (Figure 1a, Figure 1 - supplement 1b). The rate of celiac disease (9.6%) is also highly elevated over that of the general population³³. We observed 10 cases (2.2%) of juvenile Type I diabetes, which has been reported to be more common in DS^{31,32}. Other autoimmune conditions common in the general population, such as systemic lupus erythematosus or multiple sclerosis, were not observed in the HTP cohort. In the general population, the risk of autoimmune conditions increases with age and is higher in females, with autoimmune conditions tending to cluster, whereby occurrence of one autoimmune condition predisposes to a second condition^{34,35}. Within the HTP cohort, analysis of age trajectories of immune-related conditions in DS revealed early onset, with >80% of AITD, autoimmune/inflammatory skin conditions, and celiac disease being diagnosed in the first two decades of life (Figure 1 - supplement

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

1c-e). The cumulative burden of autoimmunity and autoinflammation is similar in males versus females with DS, albeit with slightly increased rates of AITD and hidradenitis suppurativa in females (Figure 1 supplement 1f). In terms of co-occurrence, when evaluating the adult population (18+ years old) for AITD, autoimmune/inflammatory skin conditions and celiac disease, we found that 75% of participants had a history of at least one condition, 38.4% had at least two, and 13.6% had three or more conditions (Figure 1b). Interestingly, analysis of medical records found an unexpectedly low number of individuals with records of autoantibodies against the thyroid gland [4.3%, e.g., anti-thyroid peroxidase (TPO), antithyroglobulin (TG)] within the HTP cohort (Figure 1 - supplement 1a). This could be explained by the fact that thyroid disease is commonly diagnosed through measurements of thyroid-relevant hormones (TSH, T3, T4) without concurrent testing of autoantibodies. To investigate further, we measured anti-TPO levels as well as levels of anti-nuclear antibodies (ANA), a more general biomarker of autoimmunity (Supplementary file 2). Remarkably, 82.4% of adults with DS show positivity for at least one of these autoantibodies, with 41.2% being positive for both (Figure 1c). Indeed, 62% of individuals with history of hypothyroidism were TPO+, whereby anti-TPO is just one of the possible autoantibodies associated with AITD. Prompted by these results, we next completed a more comprehensive analysis of autoantibodies in DS using protein array technology, with a focus on ~380 common autoepitopes from 270 proteins (see Materials and Methods, Supplementary file 2). These efforts identified 25 autoantibodies significantly over-represented in people with DS relative to age- and sex-matched controls (Figure 1d), with 98.3% of individuals with DS being positive for at least one of these autoantibodies, and 63.3% being positive for six or more (Figure 1d-e). In addition to autoantibodies against TPO, which is expressed exclusively in the thyroid gland, we identified autoantibodies targeting proteins that are either broadly expressed across multiple tissues (e.g., TOP1, UBA1, LAMP2) or preferentially expressed in specific organs across the human body, including liver (e.g., CYP1A2), pancreas (e.g., SLC30A8), skin (e.g., DSG3), bone marrow (e.g. SRP68), and brain tissue (e.g., AIMP1) (Figure 1d, f).

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

Analysis of autoantibody positivity relative to history of co-occurring conditions produced several interesting observations. Expectedly, individuals with hypothyroidism are more likely to be positive for anti-TPO antibodies (Figure 1g-h). However, unexpectedly, TPO+ status also associates with higher rates of use of pressure equalizing (PE) tubes employed to alleviate the symptoms of recurrent ear infections and otitis media with effusion (OME), which is common in DS³⁶ (Figure 1g-h). Possible interpretations for this result are provided in the Discussion. Positivity for additional autoantibodies was more common in those with other co-occurring neurological conditions, a broad classification encompassing various seizure disorders, movement disorders, and structural brain abnormalities (Figure 1g-h, Figure 1 – figure supplement 1g). Salient examples are antibodies against MUSK, a muscle-associated receptor tyrosine kinase involved in clustering of the acetylcholine receptors in the neuromuscular junction³⁷; UBA1, a ubiquitin conjugating enzyme involved in antigen presentation³⁸; and MYH6, a cardiac myosin heavy chain isoform (Figure 1g-h, Figure 1 – figure supplement 1g). Individuals with history of tricuspid valve regurgitation display higher rates of four different autoantibodies, most prominently against WARS1, a tryptophan tRNA synthetase mutated in various neurodevelopmental disorders³⁹, and SRP68, a protein commonly targeted by autoantibodies in necrotizing myopathies⁴⁰ (Figure 1 – figure supplement 1g). Individuals with a history of frequent pneumonia present a higher frequency of autoantibodies against DSG3 (desmoglein 3), a cell adhesion molecule targeted by autoantibodies in paraneoplastic pemphigus (PNP), an autoimmune disease of the skin and mucous membranes that can involve fatal lung complications⁴¹ (**Figure 1g-h**). Altogether, these results demonstrate widespread multi-organ autoimmunity across the lifespan in people with DS, with production of multiple autoantibodies that could potentially contribute to a number of co-occurring conditions more common in this population.




Figure 1. Multi-organ autoimmunity and widespread autoantibody production in Down syndrome. a, Overview of autoimmune and inflammatory conditions prevalent in persons with Down syndrome (DS) enrolled in the Human Trisome Project (HTP) cohort study. Percentages indicate the fraction of participants (n=441, all ages) with history of the indicated conditions. **b,** Pie chart showing

174

175

176

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

autoimmune/inflammatory condition burden in adults (n=278, 18+ years old) with DS. c, Pie chart showing rates of positivity for anti-TPO and/or anti-nuclear antibodies (ANA) in adults (n=212, 18+ years old) with DS. d, Bubble plot displaying odds-ratios and significance for 25 autoantibodies with elevated rates of positivity in individuals with DS (n=120) versus 60 euploid controls (D21), q values calculated by Benjamini-Hochberg adjustment of p-values from Fisher's exact test. e, Pie chart showing fractions of adults with DS (n=120, 18+ years old) testing positive for various numbers of the autoantibodies identified in d. f. Representative examples of autoantibodies more frequent in individuals with T21 (n=120) versus euploid controls (D21, n=60). MAD: median absolute deviation. Dashed lines indicate the positivity threshold of 90th percentile for D21. Data are presented as modified sina plots with boxes indicating quartiles. g. Bubble plots showing the relationship between autoantibody positivity and history of various clinical diagnoses in DS (n=120). Size of bubbles is proportional to -log-transformed p values from Fisher's exact test. h. Sina plots displaying the levels of selected autoantibodies in individuals with DS with or without the indicated co-occurring conditions. MAD: median absolute deviation. Dashed lines indicate the positivity threshold of 90th percentile for D21. Sample sizes are indicated under each plot. q values calculated by Benjamini-Hochberg adjustment of p-values from Fisher's exact tests.




Figure 1 – figure supplement 1. Early onset multi-organ autoimmunity and autoantibody production in Down syndrome. a-b, Upset plots showing overlap between various reported diagnoses indicative of autoimmune thyroid disease (a) or autoimmune/inflammatory skin conditions (b) in research participants with Down syndrome (DS, all ages, n=441) enrolled in the Human Trisome Project (HTP). c-

195

196

197

e, Plots showing the percentages of cases by age at diagnosis for AITD (c), autoimmune/inflammatory skin conditions (d), and celiac disease (e). Sample sizes indicated in each chart. f, Odds ratio plot for Fisher's exact test of proportions (cases vs. controls in males vs. females) for history of co-occurring conditions in individuals with DS (all ages, total n=441). Conditions with q < 0.1 (10% FDR) are highlighted in red. The size of square points is inversely proportional to q value; error bars represent 95% confidence intervals. g, Sina plots displaying the levels of select autoantibodies in individuals with DS, with or without history of the indicated co-occurring conditions. MAD: median absolute deviation. Horizontal dashed lines indicate 90th percentiles for the D21 group. Sample sizes are indicated under each plot. q values calculated by Benjamini-Hochberg adjustment of p-values from Fisher's exact tests.

Trisomy 21 causes global immune remodeling regardless of evident clinical autoimmunity.

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

Several immune cell changes have been proposed to underlie the autoimmunity-prone state of DS^{15,16,25,42}, but specific immune cell-to-phenotype associations have not been established in previous studies using smaller sample sizes. Therefore, we next investigated immune cell changes associated with various clinical and molecular markers of autoimmunity in DS. Toward this end we analyzed mass cytometry data from 292 individuals with DS relative to 96 euploid controls and tested for potential differences in immune cell subpopulations, identified using FlowSOM⁴³, within the DS cohort based on number of autoimmune/inflammatory disease diagnoses, ANA positivity, TPO positivity, and positivity for additional autoantibodies. In agreement with previous analyses 15,16,25,42, we observed massive immune remodeling in all major myeloid and lymphoid subsets, including increases in basophils, along with depletion of eosinophils and total B cells (Figure 2a-c, Figure 2 – figure supplement 1a-c). When comparing various subgroups within the DS cohort based on autoimmunity status, we observed that these global immune changes are largely independent of the presence of clinical diagnoses or autoantibody positivity, with very few additional changes significantly associated with these measures of autoimmunity (Figure 2 – figure supplement 1d). For example, the significant depletion of B cells and enrichment of basophils in DS is not significantly different among the various subgroups (Figure 2c, Figure 2 – figure supplement 1c). Among CD45+ CD66lo non-granulocytes, most changes are conserved among subgroups, with the sole of exception of non-classical monocytes, which are further elevated in the ANA+ group (Figure 2 – figure supplement 1d-e). Among T cells, the overall pattern of depletion of naïve subsets and enrichment of differentiated subsets characteristic of DS^{15,16,28,42} is conserved across subgroups, as illustrated by consistent depletion of CD8+ naïve subsets along with increases in the CD8+ terminally differentiated effector memory (TEMRA) subset (Figure 2f, Figure 2 – figure supplement 1d). Notably, we observed depletion of γδ T cells (both total and CD8+) in those with multiple autoimmune diagnoses (Figure 2 - figure supplement 1d, f), a result that is in line with reports documenting depletion of these subsets from peripheral circulation toward sites of active autoimmunity⁴⁴.

We also observed slight elevation of CD4+ T central memory cells (TCM) (Figure 2 – figure supplement 1d, f). Among B cells, the overall shift toward more differentiated states such as plasmablasts, age-associated B cells (ABCs), and IgM+ memory cells is also conserved among subgroups, with the sole exception of ABCs, which tend to be further elevated in the TPO+ group (Figure 2g-i, Figure 2 – figure supplement 1d, g).

Altogether, these results indicate that T21 causes global remodeling of the immune system toward an autoimmunity-prone and pro-inflammatory state, prior to clinically evident autoimmunity, and dwarfing any additional effects associated with confirmed diagnoses of autoimmune/inflammatory conditions or common biomarkers of autoimmunity.




Figure 2. Trisomy 21 causes global immune remodeling regardless of clinically evident autoimmunity. **a**, t-distributed Stochastic Neighbor Embedding (t-SNE) plot displaying major immune populations identified by FlowSOM analysis of mass cytometry data for all live cells (left) and color coded by significant impact of T21 (beta regression q<0.1) on their relative frequency (right). Red indicates increased frequency and blue indicates decreased frequency among research participants with T21 (n=292) versus euploid controls (D21, n=96). **b**, Volcano plot showing the results of beta regression

analysis of major immune cell populations among all live cells in research participants with T21 (n=292) versus euploid controls (D21, n=96). The dashed horizontal line indicates a significance threshold of 10% FDR (q<0.1) after Benjamini-Hochberg correction for multiple testing. **c**, Frequencies of B cells among all live cells in euploid controls (D21, n=96) versus individuals with T21 and history of 0 (n=69), 1 (n=102) or 2+ (n=121) autoimmune/inflammatory conditions. Data is displayed as modified sina plots with boxes indicating quartiles. **d-f**, Description as in a-c, but for subsets of T cells. **g-i**, Description as in a-c, but for subsets of B cells.




Figure 2 – **figure supplement 1.** Consistent remodeling of the peripheral immune system in Down syndrome. **a**, t-distributed Stochastic Neighbor Embedding (t-SNE) plot displaying major immune populations identified by FlowSOM analysis of mass cytometry data for CD45+ CD66^{lo} nongranulocytes (left) and color coded by the impact of trisomy 21 (T21) on their relative frequency (right). Red indicates increased frequency and blue indicates decreased frequency among research participants with T21 (n=292) versus euploid controls (D21, n=96). **b**, Volcano plot showing the results of beta regression analysis of immune cell populations among CD45+ CD66^{lo} non-granulocytes from research participants with T21 (n=292) versus euploid controls (D21, n=96). The dashed horizontal line indicates

a significance threshold of 10% FDR (q<0.1) after Benjamini-Hochberg correction for multiple testing.

c, Frequencies of basophils among all live cells in euploid controls (D21, n=96) versus individuals with T21 and history of 0 (n=44), 1 (n=71) or 2+ (n=88) autoimmune/inflammatory conditions. Data is displayed as modified sina plots with boxes indicating quartiles. d, Heatmap summarizing the results of beta regression testing for differences in frequencies of indicated immune cell populations among all live cells, CD45+ CD66^{lo} non-granulocytes, T cells, and B cells by T21 (n=292) versus D21 (n=96) status, or by different subgroups within the T21 cohort: 2+ (n=88) versus 0 (n=44) autoimmune/inflammatory conditions; TPO+ (n=144) versus TPO- (n=148); ANA+ (n=124) versus ANA- (n=49); or positivity for 8-20 (n=49) versus 0-7 (n=54) autoantibodies elevated in DS. Asterisks indicate significance after Benjamini-Hochberg correction for multiple testing (q<0.1, 10% FDR). e-g, Representative examples of immune cell populations from d, showing effects of ANA positivity (e), number of autoimmune conditions (f), and TPO status (g). Data are presented as modified sina plots with boxes indicating quartiles, with q-values indicating beta regression significance after Benjamini-Hochberg correction for multiple testing.

Trisomy 21 causes hypercytokinemia from an early age independent of autoimmunity status.

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

It is well established that individuals with DS display elevated levels of many inflammatory markers. including several interleukins, cytokines, and chemokines known to drive autoimmune conditions, such as IL-6 and TNF- $\alpha^{18,28,42,45}$. However, the interplay between hypercytokinemia, individual elevated cytokines, and development of autoimmune conditions in DS remains to be elucidated. Therefore, we analyzed data available from the HTP cohort for 54 inflammatory markers in plasma samples from 346 individuals with DS versus 131 euploid controls and cross-referenced these data with the presence of autoimmune conditions and autoantibodies. These efforts confirmed the notion of profound hypercytokinemia in DS^{18,28,42,45}, with significant elevation of multiple acute phase proteins (e.g. CRP, SAA, IL1RA), pro-inflammatory cytokines (TSLP, IL-17C, IL-22, IL-17D, IL-9, IL-6, TNF-α) and chemokines (IP-10, MIP-3a, MIP-1a, MCP-1, MCP-4, Eotaxin), as well as growth factors associated with inflammation and wound healing (FGF, PIGF, VEGF-A) (Figure 3a). However, when evaluating for differences within the DS cohort based on various metrics of autoimmunity, we did not observe important differences based on number of autoimmune/inflammatory conditions, ANA or TPO positivity status, or number of other autoantibodies (Figure 3a). For example, CRP, IL-6, and TNF- α are equally elevated across all these subgroups (Figure 3b-d, Figure 3 - figure supplement 1a). Previous studies have reported signs of early immunosenescence and inflammaging in DS, including accelerated progression of immune lineages toward terminally differentiated states, early thymic atrophy, and elevated levels of pro-inflammatory markers associated with age in the typical population^{25,27,46,47}. However, the extent to which the inflammatory profile of DS represents accelerated ageing versus other processes remains ill-defined. To address this, we first identified age-associated changes in immune markers within the euploid and DS cohorts separately (Figure 3 - figure supplement 1b-c). This exercise identified multiple immune markers that were up- or down-regulated with age, with an overall conserved pattern of age trajectories in both groups (Figure 3 - figure supplement 1c). For example, increased age is associated with increased CRP levels and decreased IL-17B levels in both cohorts (Figure 3 - figure

supplement 1d). We then compared the effects of age versus T21 status on cytokine levels in the DS cohort, which identified many inflammatory factors elevated in DS across the lifespan that do not display a significant increase with age, such as IL-9 and IL-17C, or that increase with age only in the DS cohort, such as IP-10 (Figure 3e-f, Figure 3 - figure supplement 1e).

Altogether, these results indicate that T21 induces a constitutive hypercytokinemia from early childhood, with only a fraction of these inflammatory changes being exacerbated with age.




Figure 3. Trisomy 21 causes constitutive hypercytokinemia independent of autoimmunity status from an early age. a, Heatmap displaying log₂-transformed fold-changes for plasma immune markers with significant differences in trisomy 21 (T21, n=346) versus euploid (D21, n=131), and between different subgroups within the T21 cohort: history of 2+ (n=139) versus 0 (n=87)

autoimmune/inflammatory conditions (AI conds.); TPO+ (n=133) versus TPO- (n=162); ANA+ (n=100) versus ANA- (n=39); or positivity for 8-20 (n=57) versus 0-7 (n=62) autoantibodies (AutoAbs) elevated in DS. Asterisks indicate linear regression significance after Benjamini-Hochberg correction for multiple testing (q<0.1, 10% FDR). **b-d**, Comparison of CRP, IL-6 and TNF-α levels in euploid controls (D21, n=131) versus subsets of individuals with T21 based on number of autoimmune/inflammatory conditions (**b**), ANA positivity (**c**) or TPO positivity (**d**). Data are presented as modified sina plots with boxes indicating quartiles. Samples sizes as in a. q-values indicate linear regression significance after Benjamini-Hochberg correction for multiple testing. **e**, Scatter plot comparing the effect of T21 karyotype versus the effect of age in individuals with T21 (n=54 immune markers in 346 individuals with T21), highlighting immune markers that are significantly different by T21 status, age, or both. ns: not significantly different by T21 status or age. **f**, Scatter plots for example immune markers that are significantly elevated in T21, but which are either not elevated with age in the euploid (D21) cohort (i.e., IP-10), or in either the T21 (n=346) or D21 (n=131) cohorts. Lines represent least-squares linear fits with 95% confidence intervals in grey.




Figure 3 – figure supplement 1. Consistent hypercytokinemia from an early age in Down syndrome. a, Comparison of CRP, IL-6, and TNF-α levels in euploid controls (D21, n=131) versus subsets of individuals with T21 based on number of autoantibodies commonly elevated in Down syndrome: 0-7 autoantibodies (n=62) versus 8-20 autoantibodies (n=57). Data are presented as modified

sina plots with boxes indicating quartiles. q-values indicate linear regression significance after Benjamini-Hochberg correction for multiple testing. **b**, Volcano plots presenting the results of linear regression testing for association between age and the levels of 54 immune markers in the plasma of euploid controls (left, D21, n=131) and individuals with trisomy 21 (right, T21, n=346) enrolled in the Human Trisome Project (HTP) study. Horizontal dashed lines indicate a significance threshold of 10% FDR (q<0.1) after Benjamini-Hochberg correction for multiple testing. **c**, Heatmap comparing the effect of age on levels of immune markers in D21 and T21. Heatmap color scale represents log2-transformed mean fold-change per year of age; asterisks indicate significance (q < 0.1) for linear regression testing. **d**, Scatter plots showing the age trajectories of select immune markers in D21 versus T21. Sample sizes as in c. Lines represent least squares linear fits with shaded areas indicating 95% confidence interval. **e**, Diagram representing the overlap between immune markers elevated in T21 versus D21 and those elevated with age in T21.

A clinical trial for JAK inhibition in Down syndrome.

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

Several lines of evidence support the notion that IFN hyperactivity and downstream JAK/STAT signaling are key drivers of immune dysregulation in DS^{15-19,22,24,42,48}. In mouse models of DS, both normalization of IFNR gene copy number and pharmacologic JAK1 inhibition rescue their lethal immune hypersensitivity phenotypes^{22,48}. Furthermore, we recently demonstrated that IFN transcriptional scores derived from peripheral immune cells correlate significantly with the degree of immune remodeling and hypercytokinemia in DS⁴², and we and others have reported the safe use of JAK inhibitors for treatment of diverse immune conditions in DS, including alopecia areata⁴⁹, psoriatic arthritis⁵⁰ and hemophagocytic lymphohistocytosis⁵¹ through small case series. Encouraged by these results, we launched a clinical trial to assess the safety and efficacy of the JAK inhibitor tofacitinib (Xeljanz, Pfizer) in DS, using moderateto-severe autoimmune/inflammatory skin conditions as a qualifying criterion (NCT04246372). This trial is a single-site, open-label, Phase II clinical trial enrolling individuals with DS between the ages of 12 and 50 years old affected by alopecia areata, hidradenitis suppurativa, psoriasis, atopic dermatitis, or vitiligo (see qualifying disease scores in Supplementary file 3). After screening, qualifying participants are prescribed 5 mg of tofacitinib twice daily for 16 weeks, with an optional extension to 40 weeks (Figure 4a, see Materials and Methods). After enrollment and assessments at a baseline visit, participants attend five safety monitoring visits during the main 16-week trial period. The recruitment goal for this trial is 40 participants who complete 16 weeks of tofacitinib treatment, with an IRB-approved qualitative interim analysis triggered when the first 10 participants completed the main 16-week trial (Figure 4b). Among the first 13 participants enrolled, one participant withdrew shortly after enrollment, one was excluded from analyses due to medication non-compliance (i.e., >15% missed doses), and one participant had not yet completed the trial at the time of the interim analysis (Figure 4b). Demographic characteristics of the 10 participants included in the interim analysis are shared in **Supplementary file 3**. Baseline qualifying conditions of the 10 participants included in the interim analysis were alopecia areata (n=6), hidradenitis suppurativa (n=3), and psoriasis (n=1) (open circles in **Figure 4c**). Two participants presented with concurrent atopic dermatitis, two with concurrent vitiligo, and two with concurrent hidradenitis suppurativa, albeit below the severity required to be the qualifying conditions (see closed circles in **Figure 4c**). In addition, seven participants had AITD/TPO+ and three had a celiac disease diagnosis (**Figure 4c**).

Tofacitinib is well tolerated in Down syndrome.

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

Analysis of adverse events (AEs) recorded for the 10 first participants over 16 weeks did not identify any AEs considered definitely related to tofacitinib treatment or classified as severe. Several AEs were annotated as 'possibly related' to treatment (Figure 4d, Supplementary file 4). Five episodes of upper respiratory infections (URIs) affecting five different participants were observed. Based on the safety data for tofacitinib in the general population⁵², all episodes of URIs were annotated as possibly related to treatment. Participant AA2 developed occasional cough and rhinorrhea that resolved with over-thecounter medication. Two other participants reported transient rhinorrhea (AA3, AA5), Participant AA4 developed a nasal congestion, with chest pain and a productive cough. This participant tested negative for SARS-Co-V2, Flu A-B, and RSV. Tofacitinib was not paused during this episode, and symptoms resolved with over-the-counter medication. Participant HS2 experienced a sore throat with middle ear inflammation that resolved with over-the-counter treatment. This participant also presented with folliculitis, which resolved with antibiotic treatment. Participant HS1 experienced a short transient elevation (<3 days) in creatine phosphokinase (CPK) that resolved spontaneously, and rash acneiform. Participant Ps1 experienced a transient and asymptomatic decrease in white blood cell (WBC) counts that resolved by the end of the trial.

Overall, to facitinib treatment was not discontinued for any of the 10 participants over the 16-week study period, and seven participants eventually obtained off-label prescriptions after completing the trial and are currently taking the medicine. Based on these interim results, recruitment resumed and is ongoing.




Figure 4. Clinical trial for JAK inhibition in Down syndrome. **a**, Schedule of activities for clinical trial of JAK inhibition in Down syndrome (NCT04246372). **b**, Consort chart for first 13 participants enrolled in the clinical trial. **c**, Upset plot displaying the qualifying and co-occurring autoimmune/inflammatory conditions for the 10 participants included in the interim analysis. **d**, Upset plots summarizing the adverse events annotated for the first 10 participants over a 16-week treatment period.

Tofacitinib improves diverse autoimmune/inflammatory skin conditions in Down syndrome.

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

In the clinical trial, skin pathology is monitored using global metrics of skin health, including the Investigator's Global Assessment (IGA) and the Dermatology Life Quality Index (DLOI), as well as disease-specific scores, such as the severity of alopecia tool (SALT), the psoriasis area and severity index (PASI), or the eczema area and severity index (EASI) (see Materials and Methods, Supplementary file 5. The interim analysis showed that seven of the ten participants had an improvement in the IGA score and eight of the ten reported some improvement on their life quality related to their skin condition as measured by the DLOI (Figure 5a-b). The most striking effects were observed for alopecia areata (Figure 5c-d, Figure 5 – figure supplement 1a). Five of six participants with alopecia areata showed scalp hair regrowth, with the exception being a male participant (AA1) with history of alopecia totalis for 20+ years who only showed facial hair and eyelash re-growth. One participant presented with psoriasis due to psoriatic arthritis and experienced an almost complete remission of psoriatic arthritis symptoms (Ps1, Figure 5 – figure supplement 1b-c). For the two participants that presented with atopic dermatitis, the clinical manifestations were markedly reduced during to facitinib treatment (Figure 5e-f). A total of five participants were affected by HS, three of them as the qualifying condition (HS1-3). No clear trend was seen in the Modified Sartorius Scale (MSS) score used to monitor HS (Figure 5 – figure supplement 1d**e**). Altogether, these results indicate that JAK inhibition could provide therapeutic benefit for several




Figure 5. Tofacitinib improves diverse immune skin pathologies in Down syndrome. a-b, Investigator global assessment (IGA) scores (a) and Dermatological Life Quality Index (DLQI) scores (b) for the first 10 participants at baseline visit (B), mid-point (8 weeks) and endpoint (16 weeks) visits. MD: median difference. c, Severity of Alopecia Tool (SALT) scores for the first seven participants with alopecia areata in the trial. d, Images of participant AA6 at baseline versus week 16. e, Eczema Area and Severity Index (EASI) scores for two participants with mild atopic dermatitis. f, Images of participant AA2 showing improvement in atopic dermatitis upon tofacitinib treatment. p values not shown as per interim analysis plan.




Figure 5 – **figure supplement 1. Tofacitinib improves diverse skin pathologies in Down syndrome. a,** Images of five participants with alopecia areata at baseline and after 16 weeks of tofacitinib treatment. **b-c,** Psoriasis Area and Severity Index score (b) and images (c) for participant with psoriatic arthritis. **d,**Modified Sartorius Scale (MSS) scores for five participants with hidradenitis suppurativa (HS). MD:

- median difference. e, Images for participant affected by HS at baseline and 16-week endpoint visit. p
- values not shown as per interim analysis plan.

Tofacitinib normalizes IFN scores and decreases pathogenic cytokines and autoantibodies.

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

It is well demonstrated that individuals with DS display elevated IFN signaling across multiple immune and non-immune cell types^{15-17,19}. Using an IFN transcriptional score composed of 16 interferonstimulated genes (ISGs)⁵³ measured via bulk RNA sequencing of peripheral blood RNA, individuals with DS in the HTP cohort study show a significant increase in these scores⁴⁸ (Figure 6a). Reduction of IFN scores is designated as a primary endpoint in the trial. At baseline, clinical trial participants show IFN scores within the typical range for DS, but values are decreased at 2, 8, and 16 weeks of tofacitinib treatment (Figure 6a, Supplementary file 6). Time course analysis revealed that most participants show a decrease in IFN scores as soon as two weeks of treatment which is sustained over time, with two clear exceptions (Figure 6 – figure supplement 1a). At the 8-week study midpoint, 9 of 10 participants had decreased IFN scores relative to baseline, except participant AA2 who reported a COVID-19 vaccination three days prior to the visit and was pausing to facitinib at the time of the blood draw (Figure 6 -figure supplement 1a). At the 16-week time point, nine of ten participants had decreased IFN scores, with the exception being AA4, who developed an URI in the week prior to the blood draw (Figure 6 – figure supplement 1a). Therefore, although all participants displayed decreased IFN scores at one or more time points during the treatment, IFN scores could be sensitive to immune triggers. Analysis of individual ISGs composing the IFN score revealed that whereas many ISGs elevated in DS display reduced expression upon tofacitinib treatment (e.g., RSAD2, IFI44L), others do not (e.g., BPGM) (Figure 6b, Figure 6 – figure supplement 1b). To investigate this further, we defined the impact of tofacitinib on all 136 ISGs significantly elevated in DS that are not encoded on chr21⁴² (Figure 6c). Collectively, ISGs as a group are significantly downregulated upon tofacitinib treatment, but the effect is not uniform across all ISGs (Figure 6c), indicating that JAK1/3 inhibition does not reduce all IFN signaling elevated in DS, which could be explained by the fact that the IFN pathways also employ JAK2 for signal transduction^{54,55}. Global analysis of transcriptome changes revealed that to facitini treatment reverses the dysregulation of many gene signatures observed in DS, effectively attenuating many pro-inflammatory signatures beyond IFN

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

gamma and alpha responses, such as Inflammatory Response, TNF-α signaling via NFkB, IL-2 STAT5 signaling, and IL-6 JAK STAT3 signaling (Figure 6 – figure supplement 1c). Tofacitinib also reversed elevation of genes involved in Oxidative Phosphorylation and dampened downregulation of gene sets involved in Wnt/Beta Catenin and Hedgehog Signaling (Figure 6 – figure supplement 1c-d). Conversely, tofacitinib did not rescue elevation of genes involved in Heme Metabolism or Mitotic Spindle (Figure 6 - figure supplement 1c-d), suggesting that these transcriptome changes are not tied to the inflammatory profile of DS. A secondary endpoint in the trial is decrease of peripheral inflammatory markers as defined by a composite cytokine score derived from measurements of TNF-α, IL-6, CRP, and IP-10, and which is significantly increased in participants with DS in the HTP study (Figure 6d). At baseline, clinical trial participants show cytokine scores within the range observed for DS, but these values decrease at 2, 8 and 16 weeks relative to baseline (Figure 6d-e, Figure 6 – figure supplement 1e). The decreases in TNF- α and IL-6 observed upon tofacitinib treatment indicates that elevation of these potent inflammatory cytokines requires sustained JAK/STAT signaling in DS (Figure 6e). As for the IFN scores assessment, time course analysis revealed that most participants show decreases in cytokine scores within two weeks of treatment that are sustained over time, again with the exception of AA2 at week 8 and AA4 at week 16. This reveals a correspondence between RNA-based transcriptional IFN scores and circulating levels of these cytokines in plasma, while also illustrating that both metrics may remain sensitive to immune triggers (Figure 6 – figure supplement 1f-g). One tertiary endpoint of the trial investigates the impact of tofacitinib treatment on levels of autoantibodies and markers employed to diagnose AITD [e.g., anti-TPO, anti-TG, anti-thyroid stimulating hormone receptor (TSHR)] and celiac disease [e.g., anti-tissue transglutaminase (tTG), anti-deamidated gliadin peptide (DGP)]. Seven of the 10 participants presented at baseline with anti-TPO levels above the upper limit of normal (ULN, 60U/mL), and all seven experienced a decrease in these auto-antibodies at 8 weeks and 16 weeks relative to baseline (Figure 6f). In fact, for one participant (HS1) the levels decreased

below the ULN while on the trial. All seven of these participants had a history of thyroid disease (Figure 4c), which was being medically managed and/or clinically monitored with acceptable TSH and T4 values. Additionally, three of these seven participants also had anti-TG levels above the ULN (4 IU/mL) and all three showed a decrease from baseline levels while on tofacitinib at both 8 and 16 weeks, with one participant (AA6) falling below the ULN upon treatment (Figure 6f). Three participants also had anti-TSHr levels above the ULN, but no clear changes were observed upon treatment (Supplementary file 5). None of the 10 participants displayed anti-tTG or anti-DGP levels detected above ULN at screening.

Altogether, these results indicate that tofacitinib treatment decreases IFN scores, levels of key pathogenic cytokines, and key autoantibodies involved in AITD. Importantly, tofacitinib treatment lowers IFN scores and cytokine levels to within the range observed in the general population, not below, indicating that this immunomodulatory strategy can provide therapeutic benefit in DS without overt immune suppression.




Figure 6. Tofacitinib reduces IFN scores, hypercytokinemia, and pathogenic autoantibodies in Down syndrome. a, Comparison of interferon (IFN) transcriptional scores derived from whole blood transcriptome data for research participants in the Human Trisome Project (HTP) cohort study by karyotype status (D21, grey; T21, green) and the clinical trial cohort at baseline (B), and weeks 2, 8 and

512

513

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

16 of tofacitinib treatment. Data are represented as modified sina plots with boxes indicating quartiles. Sample sizes are indicated below the x-axis. Horizontal bars indicate comparisons between groups with median differences (MD) with p-values from Mann-Whitney U-tests (HTP cohort) or q-values from paired Wilcox tests (clinical trial), q value for the 16-week endpoint is not shown as per interim analysis plan. b, Heatmap displaying median z-scores for the indicated groups (as in a) for the 16 interferon-stimulated genes (ISGs) used to calculate IFN scores. c, Analysis of fold changes for 136 ISGs not encoded on chr21 that are significantly elevated in Down syndrome (T21 versus D21) at 2, 8 and 16 weeks of tofacitinib treatment relative to baseline. Sample sizes as in a. q-values above each group indicate significance of Mann-Whitney U-tests against log2-transformed fold-change of 0 (no-chance), after Benjamini-Hochberg correction for multiple testing. d, Comparison of cytokine score distributions for the HTP cohort by karyotype status (D21, T21) versus the clinical trial cohort at baseline (B) and 2, 8 and 16 weeks of tofacitinib treatment. Data are represented as modified sina plots with boxes indicating quartiles. Sample sizes are indicated below the x-axis. Horizontal bars indicate comparisons between groups with median differences (MD) with p-values from Mann-Whitney U-tests (HTP cohort) and q-values from paired Wilcox tests (clinical trial), q value for the 16-week endpoint is not shown as per interim analysis plan. e, Comparison of plasma levels of cytokines in the HTP cohort by karyotype status (D21, T21) and the clinical trial cohort at baseline (B) versus 2, 8 and 16 weeks of tofacitinib treatment. Data are represented as modified sina plots with boxes indicating quartiles. Sample sizes are indicated below x-axis. Horizontal bars indicate comparisons between groups with median differences (MD) with p-values from Mann-Whitney U-tests (HTP cohort) and q values from paired Wilcox tests (clinical trial), q value for the 16week endpoint is not shown as per interim analysis plan. f. Plots showing levels of autoantibodies against thyroid peroxidase (TPO) and thyroglobulin (TG) at baseline versus 8 and 16 weeks of tofacitinib treatment. Sample sizes are indicated in each plot.




Figure 6 – figure supplement 1. JAK inhibition reduces multiple markers of inflammation and autoimmunity in Down syndrome. a, Plot showing trajectory of IFN scores derived from whole blood transcriptome for 10 clinical trial participants at baseline (B), versus 2, 8 and 16 weeks of tofacitinib

541

542

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

treatment. b, Comparison of ISG expression in the whole blood transcriptome data from research participants in the Human Trisome Project (HTP) cohort study by karyotype status (D21, grey; T21, green) and the clinical trial cohort at baseline (B), and weeks 2, 8 and 16 of tofacitinib treatment. Data are represented as modified sina plots with boxes indicating quartiles. Sample sizes are indicated below xaxis. Horizontal bars indicate comparisons between groups with median differences (MD) with p-values from Mann-Whitney U-tests (HTP cohort) and q-values from paired Wilcox tests (clinical trial). c, Heatmap displaying the results of Gene Set Enrichment Analysis (GSEA) of global transcriptome changes in the whole blood RNA of research participants in the HTP cohort (T21, n=304; D21, n=96) versus the clinical trial cohort at 2 (n=10), 8 (n=9), and 16 weeks (n=10) of tofacitinib treatment relative to baseline (n=10). Asterisks indicate significance after correction by Benjamini-Hochberg method for multiple testing (q<0.1, 10% FDR). NES: normalized enrichment score. **d**, Analysis of fold changes for 109 genes involved in oxidative phosphorylation and 120 genes involved in heme metabolism significantly elevated in Down syndrome (T21 versus D21 in the HTP cohort) versus the clinical trial cohort at 2, 8 and 16 weeks of tofacitinib treatment relative to baseline. Sample numbers as in c. e. Comparison of CRP levels in the HTP cohort by karyotype status (D21, grey; T21, green) versus the clinical trial cohort at baseline (B) and 2, 8 and 16 weeks of tofacitinib treatment. Data are represented as modified sina plots with boxes indicating quartiles. Sample sizes are indicated below x-axis. Horizontal bars indicate comparisons between groups with median differences (MD) with p-values from Mann-Whitney U-tests (HTP cohort) and q-values from paired Wilcox tests (clinical trial). f, Plot showing trajectory of cytokine scores for 10 clinical trial participants at baseline (B), versus 2, 8 and 16 weeks of tofacitinib treatment. g, Plots showing Spearman correlations between fold changes in IFN scores versus cytokine scores at 8 and 16 weeks of tofacitinib treatment versus baseline. Sample size is n=10.

Discussion.

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

An increasing body of evidence indicates that immune dysregulation contributes to the pathophysiology of DS and that immunomodulatory therapies could provide multidimensional benefits in this population. In mouse models, triplication of four IFNR genes contributes to multiple hallmarks of DS^{48,56} and JAK inhibition attenuates global dysregulation of gene expression⁴² while rescuing key phenotypes, such as lethal immune hypersensitivity²² and CHDs²⁴. The fact that gene signatures of IFN hyperactivity are present in human embryonic tissues with T21⁵⁷ and embryonic tissues from mouse models of DS^{48,58} indicates that the harmful effects of IFN hyperactivity could start in utero, supporting the notion that DS could be understood, in part, as an inborn error of immunity with similarities to monogenic interferonopathies⁵⁹. Results presented here demonstrate that T21 causes widespread multi-organ autoimmunity of pediatric onset, with production of autoantibodies targeting every major organ system. These results justify additional efforts to define the key pathogenic autoantibodies in DS beyond those commonly associated with AITD and celiac disease. Our analysis found significant associations between specific autoantibodies and some conditions more common in DS, but the diagnostic value of these observations will require validation efforts in much larger cohorts, which could lead to a personalized medicine approach for the management of autoimmunity in DS. For example, we found autoantibodies associated with various forms of auditory dysfunction (Figure 1g), suggesting the possibility of autoimmune hearing loss in DS⁶⁰. Elevated levels of anti-TPO in individuals with history of use of ear tubes suggests an interplay between otitis media and endocrine dysfunction in DS⁶¹. For example, it is possible that recurrent ear infections cause a chronic immune stimulus that lead to eventual breach of tolerance in this autoimmunity-prone population, even perhaps through epitope mimicry⁶². Antibodies targeting MUSK, which we found to be elevated in DS and associated with co-occurring neurological phenotypes (Figure 1g-h), have been linked to development of myasthenia gravis, a chronic autoimmune neuromuscular disease that causes weakness

in the skeletal muscles⁶³. Whether MUSK antibodies associate with similar phenotypes in DS will require

further investigation. Elevation of SRP68 autoantibodies in DS (**Figure 1d,f**), which are common in necrotizing myopathies with cardiovascular involvement⁴⁰, suggests a potential autoimmune basis for musculoskeletal and cardiovascular complications in DS, which also warrants additional research.

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

We observed constitutive global immune remodeling and hypercytokinemia regardless of reported diagnoses of autoimmune disease or measurable autoantibody production from an early age, indicative of an autoimmunity-prone state throughout the lifespan. Therefore, measurements of specific immune cell types or cytokines in the bloodstream are unlikely to provide diagnostic value for autoimmunity in DS. However, antigen-specific immune assays, such as T cell or B cell activation assays, may reveal the specific timing of loss of tolerance and transition to clinical phenotypes. Future studies should also include analysis of tissue-resident immune cells, which may identify sites of local autoimmune attack in DS.

Among the many strategies that could be used to attenuate IFN hyperactivity, JAK inhibitors are the most well-studied and have the most approved indications⁶⁴. Of the more than ten globally-approved JAK inhibitors⁶⁴, we chose to employ in our clinical trial the JAK1/3 inhibitor tofacitinib, which is used to treat diverse autoimmune/inflammatory conditions and which was approved in 2020 for treatment of polyarticular course juvenile idiopathic arthritis (pcJIA) in children 2 years and older^{64,65}. Notably, all four IFNRs encoded on chr21 utilize JAK1 for signal transduction in combination with either JAK2 or TYK2, making JAK1 inhibitors the most logical choice to dampen the effects of IFNR gene triplication. As part of the clinical trial protocol, the approved interim analysis was designed to qualitatively evaluate feasibility and initial safety data on the first 10 participants completing a 16-week course of tofacitinib treatment. This analysis established that there were no AEs that required a change or cessation of tofacitinib dosing and that this medicine is well tolerated in individuals with DS. The clear benefits observed for diverse autoimmune skin conditions align with an increasing body of evidence supporting the use of JAK inhibition for immunodermatological conditions, including their recent approval for alopecia areata and atopic dermatitis in the general population^{66,67}. At this sample size, the effects of tofacitinib on HS are inconclusive. Although some participants and caregivers reported benefits in terms

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

of fewer flares of lesser severity, the MSS metric did not show a clear trend, which may reveal the need for more frequent or different types of monitoring for HS, a condition that cycles periodically in severity. Our results indicate that to facitinib does not fully suppress the immune response in people with DS, but rather attenuates IFN scores and cytokine scores to levels observed in the general population, which is an important consideration given the likely requirement for long-term use of the drug in this population. Furthermore, the effects of the drug are clearly gene-specific, highlighting the presence of inflammatory processes that may not be attenuated with this inhibitor, which could be beneficial in terms of preserving immune activity. Importantly, during treatment, both IFN scores and cytokine scores remain sensitive to immune stimuli, as evidenced by participants who had received a vaccine or experienced an URI before a blood draw (Figure 6a, Figure 6 - figure supplement 1f). Overall, it is encouraging that key inflammatory markers decreased in a relatively short timeframe, likely offering systemic benefits beyond skin pathology. Importantly, the fact that levels of IL-6 and TNF- α are reduced upon to facitinib treatment supports the use of JAK inhibitors over TNF-blockers or anti-IL-6 agents in this population. Although TNF- α -blockers are recommended to be used first in the treatment of rheumatoid arthritis in the general population⁶⁸, the value of this recommendation in people with DS remains to be defined. The clear decrease in anti-TPO and anti-TG levels indicates that autoreactive B cell function requires elevated JAK/STAT signaling, but whether this effect is cell-autonomous versus a consequence of a reduced systemic inflammatory milieu will require further investigation. Defining the effect of tofacitinib on other autoantibodies elevated in DS will also require a larger sample size and may be revealed in the full dataset after completion of this trial. Lastly, this ongoing clinical trial includes measurements of various dimensions of neurological function not reported here. Although the absence of a placebo control arm may impede a clear interpretation of any effect of JAK inhibition on cognitive function, preliminary results have prompted the design and launch of a second trial (NCT05662228) aimed at defining the relative safety and efficacy of tofacitinib, intravenous immunoglobulin (IVIG), and the benzodiazepine lorazepam for Down

syndrome Regression Disorder (DSRD), a condition characterized by sudden loss of neurological function⁶⁹.

Altogether, these findings justify both a deeper investigation of all the deleterious effects of autoimmunity and hyperinflammation in DS and the expanded testing of immunomodulatory strategies for diverse aspects of DS pathophysiology, even perhaps from an early age.

Materials and Methods.

Human Trisome Project (HTP) study.

All aspects of this study were conducted in accordance with the Declaration of Helsinki under protocols approved by the Colorado Multiple Institutional Review Board. Results and analyses presented herein are part of a nested study within the Crnic Institute's Human Trisome Project (HTP, NCT02864108, see also www.trisome.org) cohort study. All study participants, or their guardian/legally authorized representative, provided written informed consent. The HTP study has generated multiple multi-omics datasets on hundreds of research participants, some of which have been analyzed in previous studies, including whole blood transcriptome data⁴², white blood cell transcriptome data¹⁹, plasma proteomics⁴², plasma metabolomics^{19,42}, and immune mapping via flow cytometry¹⁶ and mass cytometry^{42,48}. This paper reports new analyses of select previous datasets (transcriptome, mass cytometry, MSD immune markers) within the larger multi-omics dataset of the HTP study, as well as analyses of new datasets (e.g., anti-TPO, ANA, autoantibodies), as described in detail below.

Annotation of co-occurring conditions.

Within the HTP, a clinical history for each participant is curated from both medical records and participant/family reports. Both surveys are set up as REDCap⁷⁰ instruments that collect information as a review of systems (e.g., cardiovascular, immunity, endocrine). Expert data curators complete the medical record review and evaluate answers provided by self-advocates and caregivers. In cases of discordant answers across the two instruments, medical records take precedence. De-identified demographic and clinical metadata obtained is then linked to de-identified biospecimens used to generate the various -omics (e.g., RNA sequencing) and targeted assay datasets (e.g., anti-TPO assays). For annotation of AITD, several possible entries were considered as shown in **Figure 1** – **figure supplement 1a**, including history of hypothyroidism, hyperthyroidism, Hashimoto's disease, Grave's disease, anti-TPO or -TG antibodies, and subclinical hypothyroidism. For annotation of immune skin conditions, atopic dermatitis and eczema

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

were combined and counted in a single group, as were hidradenitis suppurativa (HS), folliculitis, and 'boils'. Blood sample collection and processing. The biological datasets analyzed herein were derived from peripheral blood samples collected using PAXgene RNA Tubes (Qiagen) and BD Vacutainer K2 EDTA tubes (BD). Whole blood from PAXgene collection tubes was processed for RNA sequencing as described below. Two 0.5 mL aliquots of whole blood were withdrawn from each EDTA tube and processed for mass cytometry as described below. The remaining EDTA blood samples were centrifuged at 700 x g for 15 min to separate plasma, buffy coat containing white blood cells (WBC), and red blood cells (RBCs). Samples were then aliquoted, flash frozen and stored at -80°C until subsequent processing and analysis. Centrifugation and storage of samples took place within 2 hours of collection. Measurements of autoantibodies. Anti-TPO status was determined from plasma samples using an electrochemiluminescence-based assay 71, and carried out by the Autoantibody/HLA Core Facility of the Barbara Davis Center for Childhood Diabetes at the University of Colorado Anschutz Medical Campus. Sample values were calculated as (sample signal – negative control signal) / (positive control signal – negative control signal), with the threshold (upper limit of normal) for TPO positivity based on the 95th percentile of healthy control samples. Anti-nuclear antigen (ANA) status was determined from plasma samples using a qualitative ELISA kit (MyBioSource, cat. no. 702970) according to manufacturer instructions, with a sample OD_{450nm} / negative control OD_{450nm} ratio ≥ 2.1 evaluated as positive and a ratio ≤ 2.1 evaluated as negative. Autoantigen profiling of EDTA plasma samples (50 μ L each; T21, n = 120; D21, n = 60) was performed by the Affinity Proteomics unit at SciLifeLab (KTH Royal Institute of Technology, Stockholm, Sweden) using peptide arrays. Antigens were selected to cover potential associations to autoimmune diseases and consisted of 380 peptide fragments covering ~270 unique proteins (1-5 fragments per protein). Fragments

were ~20-163 amino acids long (median 82). All antigens were expressed in E. coli with a hexahistidyl and albumin binding protein tag (His6ABP). Using, COOH-NH2 chemistry, the analyzed antigens, in addition to controls, were immobilized on color-coded magnetic beads (MagPlex, Luminex). Controls consisted of His6ABP, buffer, rabbit anti-human IgG (loading control, Jackson ImmunoResearch), and Epstein-Barr nuclear antigen 1 (EBNA1, Abcam), Research samples and technical controls (commercial plasma; Seralab) were diluted (1:250) in assay buffer, which consisted of 3% BSA, 5% milk, 0.05% Tween-20, and 160 ug/ml His6ABP tag in PBS. Diluted samples and controls were incubated for 1 hour at room temperature then subsequently incubated with the antigen bead array for 2 hour. The reactions were then fixed for 10 minutes using 0.02% paraformaldehyde, then incubated for 30 minutes with goat Fab specific for human IgG Fc-y tagged with the fluorescent marker R-phycoerythrin (Invitrogen). Median fluorescence intensity (MFI) and number of beads for each reaction was analyzed using a FlexMap 3D instrument (Luminex Corp.). Quality control was performed using MFI and bead count to exclude antigens and samples not passing technical criteria including minimal bead counts and antigen coupling efficiency. To adjust for sample specific backgrounds, MFI values were transformed per reaction median absolute deviations (MADs) using the following calculation:

711
$$MADs_{sample} = (MFI - median_{sample(MFI)}) / MAD_{sample(MFI)}$$

Subsequent data analysis and handling was performed using R. For each antigen, positivity was defined as >90th percentile MAD value for D21 samples only. Overrepresentation of positivity for each antigen in the T21 versus D21 group was determined using Fisher's exact test, excluding antigens detected in <18 samples (<10% of total experiment). Correction for multiple testing was performed using the Benjamini-Hochberg approach and significance defined as q<0.1 (10% FDR). Similarly, within the T21 group, Fisher's exact test was used to test for overrepresentation of antigen positivity in cases versus controls for co-occurring conditions, with only those with at least 5 cases considered in the analysis.

Immune profiling via mass cytometry.

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

712

713

714

715

716

717

718

719

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

Generation of the mass cytometry dataset was described previously⁴², but a full description is included here for reference. Two 0.5 mL aliquots of EDTA whole blood samples underwent RBC lysis and white blood cell fixation using TFP FixPerm Buffer (Transcription Factor Phospho Buffer Set, BD Biosciences). WBCs were then washed in 1x in PBS (Rockland), resuspended in Cell Staining Buffer (Fluidigm) and stored at -80°C. For antibody staining, samples were thawed at room temperature, washed in Cell Staining Buffer, barcoded using a Cell-ID 20-Plex Pd Barcoding Kit (Fluidigm), and combined per batch. Each batch was able to accommodate 19 samples with a common reference sample. Antibodies were either purchased pre-conjugated to metal isotopes or conjugation was performed in-house using a Maxpar Antibody Labeling Kit (Fluidigm). See Supplementary file 7 for antibodies. Working dilutions for antibody staining were titrated and validated using the common reference sample and comparison to relative frequencies obtained by independent flow cytometry analysis. Surface marker staining was carried out for 30 min at 4°C in Cell Staining Buffer with added Fc Receptor Binding Inhibitor (eBioscience/ThermoFisher Scientific). Staining was followed by a wash in Cell Staining Buffer. Next, cells were permeabilized in Buffer III (Transcription Factor Phospho Buffer Set, BD Pharmingen) for 20 min at 4°C followed by washing with perm/wash buffer (Transcription Factor Phospho Buffer Set, BD Pharmingen). Intracellular transcription factor and phospho-epitope staining was carried out for 1 hour at 4°C in perm/wash buffer (Transcription Factor Phospho Buffer Set, BD Pharmingen), followed by a wash with Cell Staining Buffer. Cell-ID Intercalator-Ir (Fluidigm) was used to label barcoded and stained cells. Labeled cells were analyzed on a Helios instrument (Fluidigm). Mass cytometry data were exported as v3.0 FCS files for pre-processing and analysis. Analysis of mass cytometry data. Pre-processing. Bead-based normalization via polystyrene beads embedded with lanthanides, both within and between batches, followed by bead removal was carried out as previously described using the Matlabbased Normalizer tool⁷². Batched FCS files were demultiplexed using the Matlab-based Single Cell Debarcoder tool⁷³. Reference-based normalization of individual samples across batches against the

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

common reference sample was then carried out using the R script BatchAdjust(). For the analyses described in this manuscript, CellEngine (CellCarta) was used to gate and export per-sample FCS files at four levels: Firstly, CD3+CD19+ doublets were excluded and remaining cells exported as 'Live' cells; Live cells were then gated for hematopoietic lineage (CD45-positive) non-granulocytic (CD66-low) cells and exported as CD45+CD66low. Lastly, CD45+CD66low cells were gated on CD3-positivity and CD19positivity and exported as T- and B-cells, respectively. Per-sample FCS files were then subsampled to a maximum of 50,000 events per file for subsequent analysis. Unsupervised clustering. For each of the four levels (live, non-granulocytes, T cells, and B cells), all 388 per-sample FCS files were imported into R as a flowSet object using the read.flowSet() function from the flowCore R package⁷⁴. Next a SingleCellExperiment object was constructed from the flowSet object using the *prepData()* function from the CATALYST package⁷⁵. Arcsinh transformation was applied to marker expression data with cofactor values ranging from ~0.2 to ~15 to give optimal separation of positive and negative populations for each marker, using the estParamFlowVS() function from the flowVS R package⁷⁶ and based on visual inspection of marker histograms (see Supplementary file 7). Quality control and diagnostic plots were examined with the help of functions from CATALYST and the tidySingleCellExperiment R package. Unsupervised clustering using the FlowSOM algorithm⁴³ was carried out using the *cluster()* function from CATALYST, with grid size set to 10 x 10 to give 100 initial clusters and a maxK value of 40 was explored for subsequent meta-clustering using the ConsensusClusterPlus algorithm. Examination of delta area and minimal spanning tree plots indicated that 30-40 meta clusters gave a reasonable compromise between gains in cluster stability and number of clusters for each level. Each clustering level was re-run with multiple random seed values to ensure consistent results. Visualization using t-distributed stochastic neighbor imbedding (tSNE). Dimensionality reduction to two dimensions was carried out using the runDR() function from the CATALYST package, with 500 cells per sample, and using several random seed values to ensure consistent results. Multiple values of the

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

perplexity parameter were tested, with a setting of 440, using the formula Perplexity= $N^{(1/2)}$ as suggested https://towardsdatascience.com/how-to-tune-hyperparameters-of-tsne-7c0596a18868, providing a visualization with good agreement with the clusters defined by FlowSOM. Cell type classification. To aid in assignment of clusters to specific lineages and cell types, the MEM package (marker enrichment modeling) was used to call positive and negative markers for each cell cluster based on marker expression distributions across clusters. Manual review and comparison to marker expression histograms, as well as minimal spanning tree plots and tSNE plots colored by marker expression, allowed for high-confidence assignment of most clusters to specific cell types. Clusters that were insufficiently distinguishable were merged into their nearest cluster based on the minimal spanning tree. Relative frequencies for each cell type / cluster were calculated for each sample as a percentage of total live cells and as a percentage of cells used for each level of clustering: total CD45+CD66low cells, total T cells, or total B cells. Beta regression analysis. To identify cell clusters for which relative frequencies are associated with either trisomy 21 status or with various clinical subgroups (e.g. ANA+) among individuals with trisomy 21, beta regression analysis was carried out using the betareg R package, with each model using cell type cluster proportions (relative frequency) as the outcome/dependent variable and either T21 status or clinical subgroups as independent/predictor variables, along with adjustment for age and sex, and a logit link function. Extreme outliers were classified per-karyotype and per-cluster as measurements more than three times the interquartile range below or above the first and third quartiles, respectively (below Q1 - 3*IQR or above Q3 + 3*IQR) and excluded from beta regression analysis. Correction for multiple comparisons was performed using the Benjamini-Hochberg (FDR) approach. Effect sizes (as fold-change in T21 vs. euploid controls or among T21 subgroups) for each cell type cluster were obtained by exponentiation of beta regression model coefficients. Fold-changes were visualized by overlaying on tSNE plots using ggplot2. For visualization of individual clusters, data points were adjusted for age and sex, using the

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

adjust() function from the datawizard R package, and visualized as sina plots (separated by T21 status or clinical subgroup). Measurement of immune markers and calculation of cytokine scores. Briefly, from each EDTA plasma sample, two replicates of 12-25 µL were analyzed using the Meso Scale Discovery (MSD) multiplex immunoassay platform V-PLEX Human Biomarker 54-Plex Kit (HTP cohort) or U-PLEX Human Biomarker Group 1 71-Plex and V-PLEX Human Vascular Injury Panel 2 Kits (clinical trial cohort) on a MESO QuickPlex SQ 120 instrument. Assays were carried out as per manufacturer instructions. Concentration values were calculated against a standard curve with provided calibrators. MSD data are reported as concentration values in picograms per milliliter of plasma. Analysis of immune marker data. Plasma concentration values (pg/mL) for each of the cytokines and related immune factors measured across multiple MSD assay plates was imported to R, combined, and analytes with >10% of values outside of detection or fit curve range flagged. For each analyte, missing values were replaced with either the minimum (if below fit curve range) or maximum (if above fit curve range) calculated concentration per plate/batch and means of duplicate wells used for subsequent analysis. For the HTP study analysis, extreme outliers were classified per-karyotype and per-analyte as measurements more than three times the interquartile range below or above the first and third quartiles, respectively, and excluded from further analysis. Differential abundance analysis for inflammatory markers measured by MSD was performed using mixed effects linear regression as implemented in the *lmer()* function from the lmerTest R package (v3.1-2) with log2-transformed concentration as the outcome/dependent variable, T21 status or clinical subgroup (e.g., ANA+) as the predictor/independent variable, age and sex as fixed covariates, and sample source as a random effect. Multiple hypothesis correction was performed with the Benjamini-Hochberg method using a false discovery rate (FDR) threshold of 10% (q < 0.1). Prior to visualization or correlation analysis, MSD data were adjusted for age, sex, and sample source using the *removeBatchEffect()* function from the limma package (v3.44.3).

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

Calculation of cytokine scores. For comparison of clinical trial samples across time points, cytokine scores were calculated as the sum of the Z-scores for TNF-α, IL-6, CRP and IP-10. For comparison of clinical trial samples to the HTP cohort, Z-scores were first calculated from age-, sex, and batch-adjusted values for each sample, based on the mean and standard deviation of the HTP euploid control samples. Whole blood transcriptome analysis and calculation of IFN scores. Strand-specific sequencing libraries were prepared from globin-depleted, polyA-enriched whole blood RNA and sequenced on the Illumina NovaSeq platform (2x 150 bases). Data quality was assessed using FASTQC (v0.11.5) and FastQ Screen (v0.11.0). Trimming and filtering of low-quality reads was performed using bbduk from BBTools (v37.99) and fastq-mcf from ea-utils (v1.05). Alignment to the human reference genome (GRCh38) was carried out using HISAT2 (v2.1.0) in paired, spliced-alignment mode against a GRCh38 index and Gencode v33 basic annotation GTF, and alignments were sorted and filtered for mapping quality (MAPQ > 10) using Samtools (v1.5). Gene-level count data were quantified using HTSeq-count (v0.6.1) with the following options (--stranded=reverse -minaqual=10 -type=exon -mode=intersection-nonempty) using a Gencode v33 GTF annotation file. Differential gene expression in T21 versus D21 was evaluated using DESeq2 (version 1.28.1)⁷⁷, with q < 0.1 (10% FDR) as the threshold for differential expression. DS IFN scores. RNA-seq-based 'Down syndrome interferon scores' (DS IFN scores) were calculated as follows: for comparison of clinical trial samples across time points, DS IFN scores were calculated as the sum of Z-scores across 16 interferon-stimulated genes (ISGs) genes with significant mean fold-change of at least 1.5 in the HTP T21 group vs. the euploid control group, excluding IFNAR2, MX1, and MX2 which are encoded on chromosome 21. For comparison of clinical trial samples to the HTP cohort, gene-wise Zscores were first calculated from age-, sex, and sequencing batch-adjusted FPKM values for each sample, based on the mean and standard deviation of the HTP euploid control samples.

Gene set enrichment analysis (GSEA). GSEA⁷⁸ was carried out in R using the fgsea package (v1.14.0), using Hallmark gene sets, log₂-transformed fold-change values as the ranking metric.

Clinical trial design and oversight.

All aspects of this study were conducted in accordance with the Declaration of Helsinki. All study activities were approved by the Colorado Multiple Institutional Review Board (COMIRB, protocol # 19-1362, NCT04246372) with an independent Data and Safety Monitoring Board (DSMB) appointed by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Written consent was obtained from all participants, or their legally authorized representative if the participant was unable to provide consent, in which case participant assent was obtained. The Clinical Trial Protocol is provided in the **Supplementary file 8**. We report here interim results of a single-site, open-label phase 2 clinical trial enrolling individuals with DS between the ages of 12 and 50 years old with moderate-to-severe alopecia areata, hidradenitis suppurativa, psoriasis, atopic dermatitis, or vitiligo. Qualifying disease scores are shown in **Supplementary file 3**. After screening, qualifying participants are prescribed 5 mg tofacitinib twice daily for 16 weeks, with an optional extension arm to week 40. During the main 16-week trial, participants attend five safety monitoring visits after enrollment at the Baseline visit.

Trial Population.

The recruitment goal for this trial is 40 participants completing 16 weeks of tofacitinib treatment, with a qualitative interim analysis triggered when 10 participants completed the main 16-week trial. Of the 10 participants included in the interim analysis, 4 are female, 100% identify as White/Caucasian, 3 identify as Hispanic or Latino, and mean age at enrollment was 23.1 years old (range 15-38.1 years old) (**Supplementary file 3**). Baseline qualifying conditions of the 10 participants were alopecia areata: n=6 (46.1%), hidradenitis suppurativa: n=3 (30.8%), or psoriasis: n=1 (7.7%). Two participants also had atopic dermatitis, and two others had vitiligo, albeit below the severity required to be the qualifying condition.

Outcome Measures.

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

Primary endpoints. The two primary outcome measures for this trial are safety and reduction in IFN transcriptional scores derived from peripheral whole blood. Based on the safety profile for tofacitinib in the general population⁶⁸, the safety primary endpoint was defined as no more than two serious adverse events (SAEs) definitely attributable to tofacitinib over the course of 16 weeks for 40 participants. Adverse events were classified based using Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0). IFN scores are commonly used to monitor disease severity and response to treatment in IFN-driven pathologies^{79,80} and their calculation form RNAseq data is described above. Secondary endpoints. The secondary outcome measures for this trial include improvements in skin health as defined by a global assessment, the Investigator Global Assessment (IGA), as well as the diseasespecific assessments. Overall skin pathology, accounting for all present skin conditions regardless of severity, was assessed using a modified IGA which scores on a five-point scale for each skin condition (six points for HS) with a range of 0-21. Another secondary endpoint assessing global skin health is a change in the Dermatological Quality of Life Index (DLQI), used to assess participant-reported impact of skin conditions on self-image, relationships, and daily activities. Possible total scores range from 0-30, with higher scores indicating a more impaired quality of life. Condition-specific assessments used are Severity of Alopecia Tool (SALT) for AA affecting at least 25% of the scalp (qualifying score is \geq 25); Hidradenitis Suppurativa-Physicians Global Assessment (HS-PGA) to define eligibility (qualifying score >3) and Modified Sartorius Scale (MSS) to monitor changes throughout the study for HS; Psoriasis Area and Severity Index (PASI, qualifying score is ≥ 10) for psoriasis; Vitiligo Extent Tensity Index (VETI, qualifying score is ≥2), for moderate-to-severe vitiligo; and Eczema Area and Severity Index (EASI, qualifying EASI score ≥16) for moderate-to-severe atopic dermatitis. The last secondary endpoint is reduction in a cytokine score coalescing information on four inflammatory markers elevated in DS: Tumor Necrosis Factor Alpha (TNF-α), interleukin 6 (IL-6), C-reactive protein (CRP), and IFN-inducible protein 10 (IP10, CXCL10)¹⁸. Measurement of these proteins and calculation of the cytokine score is described above.

Tertiary endpoints. This clinical trial includes multiple exploratory tertiary endpoints (see full protocol in **Supplementary file 8**), including reduction in autoantibodies related to AITD (anti-TPO, anti-TG, and anti-TSHr) and celiac disease (anti-tTG, anti-DGP). In the clinical trial, these autoantibodies were assessed using established clinical assays.

Statistical Analysis.

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

The Statistical Analysis Plan (SAP) approved by the appointed DSMB is included with the Clinical Trial Protocol in the **Supplementary file 8**. This report includes analysis of the time points used to assess endpoints (baseline and 16 weeks), as well research-only time points at 2 and 8 weeks of treatment. Given the qualitative nature of this interim analysis, statistical analysis is not completed for changes observed between baseline and the 16-week endpoint. Data may be displayed as log_2 transformed for clarity in viewing the graphs.

Data Availability Statement:

Α collection with datasets used in this study is available in **Synapse** (https://doi.org/10.7303/syn53185135), with the individual datasets also accessible as detailed below. Demographic and health history data for research participants in the HTP study are available on both the Synapse data sharing platform (https://doi.org/10.7303/syn31488784) and through the INCLUDE Data Hub (https://portal.includedcc.org/). Mass cytometry data for 380+ HTP research participants are available both in Synapse (https://doi.org/10.7303/syn53185253) and FlowRepository, Study ID FR-FCM-Z5GE, https://flowrepository.org/id/RvFrQaBqhe8TGyko1OMdQKtR7HN8nulAnHW0PJkm1CEyyo8fnJg2rHr WvNrhE8xu. Targeted plasma proteomics for inflammatory markers using Meso Scale Discovery (MSD) 470 +assays **HTP** research participants be accessed through **Synapse** can (https://doi.org/10.7303/syn31475487) and the INCLUDE Data Hub. Whole blood transcriptome data for 400 HTP research participants can be accessed through Synapse (https://doi.org/10.7303/syn31488780),

the INCLUDE Data Hub, and NCBI Gene Expression Omnibus (GSE190125). Whole blood transcriptome data for 10 clinical trial participants at baseline and after 2, 8, and 16 weeks of tofacitinib treatment can be accessed through Synapse (https://doi.org/10.7303/syn53185250), and NCBI Gene Expression Omnibus (GSE PENDING). Targeted plasma proteomics for inflammatory markers using Meso Scale Discovery (MSD) assays for 10 clinical trial participants can be accessed through Synapse (https://doi.org/10.7303/syn53185252).

Code Availability Statement: No custom code or algorithms were developed during the course of this study. R analysis scripts will be made available upon request.

925	925 References.	
926	1	Lejeune, J., Turpin, R. & Gautier, M. [Mongolism; a chromosomal disease (trisomy)]. Bull Acad
927		Natl Med 143, 256-265 (1959).
928	2	Antonarakis, S. E. et al. Down syndrome. Nature reviews. Disease primers 6, 9 (2020).
929		https://doi.org:10.1038/s41572-019-0143-7
930	3	Chicoine, B. et al. Prevalence of Common Disease Conditions in a Large Cohort of Individuals
931		With Down Syndrome in the United States. J Patient Cent Res Rev 8, 86-97 (2021).
932		https://doi.org:10.17294/2330-0698.1824
933	4	Amr, N. H. Thyroid Disorders in Subjects with Down Syndrome: An Update. Acta Biomed 89,
934		132-139 (2018). https://doi.org:10.23750/abm.v89i1.7120
935	5	Pierce, M. J., LaFranchi, S. H. & Pinter, J. D. Characterization of Thyroid Abnormalities in a
936		Large Cohort of Children with Down Syndrome. Hormone research in paediatrics 87, 170-178
937		(2017). https://doi.org:10.1159/000457952
938	6	Iughetti, L. et al. Ten-year longitudinal study of thyroid function in children with Down's
939		syndrome. Hormone research in paediatrics 82, 113-121 (2014).
940		https://doi.org:10.1159/000362450
941	7	Book, L. et al. Prevalence and clinical characteristics of celiac disease in Downs syndrome in a
942		US study. American journal of medical genetics 98, 70-74 (2001).
943	8	Zachor, D. A., Mroczek-Musulman, E. & Brown, P. Prevalence of celiac disease in Down
944		syndrome in the United States. Journal of pediatric gastroenterology and nutrition 31, 275-279
945		(2000).
946	9	Sureshbabu, R. et al. Phenotypic and dermatological manifestations in Down Syndrome.
947		Dermatology online journal 17, 3 (2011).

948 10 Madan, V., Williams, J. & Lear, J. T. Dermatological manifestations of Down's syndrome. 949 Clinical and experimental dermatology **31**, 623-629 (2006). https://doi.org:10.1111/j.1365-950 2230.2006.02164.x 951 11 Lam, M., Lai, C., Almuhanna, N. & Alhusayen, R. Hidradenitis suppurativa and Down 952 syndrome: A systematic review and meta-analysis. *Pediatric dermatology* **37**, 1044-1050 (2020). 953 https://doi.org:10.1111/pde.14326 954 12 Arava, P. et al. IGF1 deficiency integrates stunted growth and neurodegeneration in Down 955 syndrome. Cell reports 41, 111883 (2022). https://doi.org:10.1016/j.celrep.2022.111883 956 13 Flores-Aguilar, L. et al. Evolution of neuroinflammation across the lifespan of individuals with 957 Down syndrome. Brain 143, 3653-3671 (2020). https://doi.org:10.1093/brain/awaa326 958 14 Wilcock, D. M. & Griffin, W. S. T. Down's syndrome, neuroinflammation, and Alzheimer 959 neuropathogenesis. Journal of neuroinflammation 10, 864 (2013). https://doi.org:10.1186/1742-960 2094-10-84 961 15 Waugh, K. A. et al. Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage 962 Hypersensitivity to Type I Interferon in Down Syndrome. Cell reports 29, 1893-1908 e1894 963 (2019). https://doi.org:10.1016/j.celrep.2019.10.038 964 16 Araya, P. et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state 965 associated with interferon hyperactivity. *Proc Natl Acad Sci U S A* **116**, 24231-24241 (2019). 966 https://doi.org:10.1073/pnas.1908129116 967 17 Sullivan, K. D. et al. Trisomy 21 consistently activates the interferon response. Elife 5 (2016). 968 https://doi.org:10.7554/eLife.16220 18 969 Sullivan, K. D. et al. Trisomy 21 causes changes in the circulating proteome indicative of 970 chronic autoinflammation. Scientific reports 7, 14818 (2017). https://doi.org:10.1038/s41598-971 017-13858-3

972 19 Powers, R. K. et al. Trisomy 21 activates the kynurenine pathway via increased dosage of 973 interferon receptors. Nat Commun 10, 4766 (2019). https://doi.org:10.1038/s41467-019-12739-9 974 Secombes, C. J. & Zou, J. Evolution of Interferons and Interferon Receptors. Front Immunol 8, 20 975 209 (2017). https://doi.org:10.3389/fimmu.2017.00209 976 21 Waugh, K. A., Minter, R., Baxter, J., Chi, C., Tuttle, K.D., Eduthan, N.P., Galbraith, M.D., 977 Kinning, K.T., Andrysik, Z., Araya, P., Dougherty, H., Dunn, L.N., Ludwig, M., Schade, K.A., 978 Tracy, D., Smith, K.P., Granrath, R.E., Busquet, N., Khanal, S., Anderson, R.D., Cox, L.L., 979 BEnriquez Estrada, B., Rachubinski, A.L., Lyford, H.R., Britton, E.C., Orlicky, D.J., Matsuda, 980 J.L., Song, K., Cox, T.C., Sullivan, K.D., and Espinosa, J.M. Interferon receptor gene dosage 981 determines diverse hallmarks of Down syndrome. BioRxiv (2022). 982 https://doi.org:https://doi.org/10.1101/2022.02.03.478982 983 22 Tuttle, K. D. et al. JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model 984 of Down Syndrome. Cell reports 33, 108407 (2020). 985 https://doi.org:10.1016/j.celrep.2020.108407 986 23 Galbraith, M. D., Rachubinski, A.L., Smith, K.P., Araya, P., Waugh, K.A., Enriquez-Estrada, B., 987 Worek, K., Granrath, R.E., Kinning, K.T., Eduthan, N.P., Ludwig, M.P. Hsieh, E.W.Y., Sullivan, 988 K.D., Espinosa, J.M. Multidimensional definition of the interferon pathy of Down syndrome and 989 its response to JAK inhibition. Science Advances 9 (2023). 990 Chi, C., Knight, W.E., Riching, A.S., Zhang, Z., Tatavosian, R., Zhuang, Y., Moldovan, R., 24 991 Rachubinski, A.L., Gao, D., Xu H., Espinosa, J.M., Song, K. . Interferon hyperactivity impairs 992 cardiogenesis in Down syndrome via downregulation of canonical Wnt signaling. iScience 26, 993 **107012** (2023). https://doi.org/10.1016/j.isci. 2023.107012 994 25 Lambert, K. et al. Deep immune phenotyping reveals similarities between aging, Down 995 syndrome, and autoimmunity. Science translational medicine 14, eabi4888 (2022). 996 https://doi.org:10.1126/scitranslmed.abi4888

997	26	Khor, B. & Buckner, J. H. Down syndrome: insights into autoimmune mechanisms. <i>Nature</i>
998		reviews. Rheumatology, 1-2 (2023). https://doi.org:10.1038/s41584-023-00970-0
999	27	Gensous, N., Bacalini, M. G., Franceschi, C. & Garagnani, P. Down syndrome, accelerated aging
000		and immunosenescence. Seminars in immunopathology (2020). https://doi.org:10.1007/s00281-
001		<u>020-00804-1</u>
002	28	Malle, L. et al. Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c(+) B
003		cells. Nature 615, 305-314 (2023). https://doi.org:10.1038/s41586-023-05736-y
004	29	Aversa, T. et al. Epidemiological and clinical aspects of autoimmune thyroid diseases in children
005		with Down's syndrome. <i>Ital J Pediatr</i> 44 , 39 (2018). https://doi.org:10.1186/s13052-018-0478-9
006	30	Liu, E. et al. Routine Screening for Celiac Disease in Children With Down Syndrome Improves
007		Case Finding. Journal of pediatric gastroenterology and nutrition 71, 252-256 (2020).
008		https://doi.org:10.1097/mpg.000000000002742
009	31	Johnson, M. B. et al. Trisomy 21 Is a Cause of Permanent Neonatal Diabetes That Is
010		Autoimmune but Not HLA Associated. Diabetes 68, 1528-1535 (2019).
011		https://doi.org:10.2337/db19-0045
012	32	Aitken, R. J. et al. Early-onset, coexisting autoimmunity and decreased HLA-mediated
013		susceptibility are the characteristics of diabetes in Down syndrome. Diabetes Care 36, 1181-
014		1185 (2013). https://doi.org:10.2337/dc12-1712
015	33	Singh, P. et al. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin
016		Gastroenterol Hepatol 16, 823-836 e822 (2018). https://doi.org:10.1016/j.cgh.2017.06.037
017	34	Markle, J. G. et al. Sex differences in the gut microbiome drive hormone-dependent regulation of
018		autoimmunity. Science 339, 1084-1088 (2013). https://doi.org:10.1126/science.1233521
019	35	Molano-Gonzalez, N. et al. Cluster analysis of autoimmune rheumatic diseases based on
020		autoantibodies. New insights for polyautoimmunity. <i>Journal of autoimmunity</i> 98 , 24-32 (2019).
021		https://doi.org:10.1016/j.jaut.2018.11.002

022	36	Elling, C. L. et al. Otitis Media in Children with Down Syndrome Is Associated with Shifts in
023		the Nasopharyngeal and Middle Ear Microbiotas. Genet Test Mol Biomarkers 27, 221-228
024		(2023). https://doi.org:10.1089/gtmb.2023.0132
025	37	Ghazanfari, N., Morsch, M., Reddel, S. W., Liang, S. X. & Phillips, W. D. Muscle-specific
026		kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the
027		mouse neuromuscular junction. J Physiol 592 , 2881-2897 (2014).
028		https://doi.org:10.1113/jphysiol.2013.270207
029	38	Poulter, J. A. et al. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood
030		137, 3676-3681 (2021). https://doi.org:10.1182/blood.2020010286
031	39	Lin, S. J. et al. Biallelic variants in WARS1 cause a highly variable neurodevelopmental
032		syndrome and implicate a critical exon for normal auditory function. <i>Hum Mutat</i> 43 , 1472-1489
033		(2022). https://doi.org:10.1002/humu.24435
034	40	Allenbach, Y., Benveniste, O., Stenzel, W. & Boyer, O. Immune-mediated necrotizing
035		myopathy: clinical features and pathogenesis. Nature reviews. Rheumatology 16, 689-701
036		(2020). https://doi.org:10.1038/s41584-020-00515-9
037	41	Amagai, M., Nishikawa, T., Nousari, H. C., Anhalt, G. J. & Hashimoto, T. Antibodies against
038		desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic
039		pemphigus and cause acantholysis in vivo in neonatal mice. The Journal of clinical investigation
040		102, 775-782 (1998). https://doi.org:10.1172/JCI3647
041	42	Galbraith, M. D. et al. Multidimensional definition of the interferonopathy of Down syndrome
042		and its response to JAK inhibition. Science Advances 9, eadg6218 (2023).
043		https://doi.org:doi:10.1126/sciadv.adg6218
044	43	Van Gassen, S. et al. FlowSOM: Using self-organizing maps for visualization and interpretation
045		of cytometry data. Cytometry A 87, 636-645 (2015). https://doi.org:10.1002/cyto.a.22625

046	44	Amini, A., Pang, D., Hackstein, C. P. & Klenerman, P. MAIT Cells in Barrier Tissues: Lessons
047		from Immediate Neighbors. Front Immunol 11, 584521 (2020).
048		https://doi.org:10.3389/fimmu.2020.584521
049	45	Zhang, Y. et al. Aberrations in circulating inflammatory cytokine levels in patients with Down
050		syndrome: a meta-analysis. <i>Oncotarget</i> 8 , 84489-84496 (2017).
051		https://doi.org:10.18632/oncotarget.21060
052	46	Kusters, M. A., Gemen, E. F., Verstegen, R. H., Wever, P. C. & E, D. E. V. Both normal
053		memory counts and decreased naive cells favor intrinsic defect over early senescence of Down
054		syndrome T lymphocytes. Pediatr Res 67, 557-562 (2010).
055		https://doi.org:10.1203/PDR.0b013e3181d4eca3
056	47	Trotta, M. B. et al. Inflammatory and Immunological parameters in adults with Down syndrome.
057		Immun Ageing 8, 4 (2011). https://doi.org:10.1186/1742-4933-8-4
058	48	Waugh, K. A. et al. Triplication of the interferon receptor locus contributes to hallmarks of
059		Down syndrome in a mouse model. <i>Nature genetics</i> (2023). https://doi.org:10.1038/s41588-023-
060		01399-7
061	49	Rachubinski, A. L. et al. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic
062		benefit for alopecia areata. JAAD Case Rep 5, 365-367 (2019).
063		https://doi.org:10.1016/j.jdcr.2019.02.007
064	50	Pham, A. T. et al. JAK inhibition for treatment of psoriatic arthritis in Down syndrome.
065		Rheumatology (2021). https://doi.org:10.1093/rheumatology/keab203
066	51	Guild, A., Fritch, J., Patel, S., Reinhardt, A. & Acquazzino, M. Hemophagocytic
067		lymphohistocytosis in trisomy 21: successful treatment with interferon inhibition. Pediatr
068		Rheumatol Online J 20, 104 (2022). https://doi.org:10.1186/s12969-022-00764-w

069	52	Cohen, S. B. et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to
070		8.5 years: integrated analysis of data from the global clinical trials. <i>Ann Rheum Dis</i> 76 , 1253-
071		1262 (2017). https://doi.org:10.1136/annrheumdis-2016-210457
072	53	Honda, K., Takaoka, A. & Taniguchi, T. Type I interferon [corrected] gene induction by the
073		interferon regulatory factor family of transcription factors. <i>Immunity</i> 25 , 349-360 (2006).
074		https://doi.org:10.1016/j.immuni.2006.08.009
075	54	Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory
076		diseases. <i>Nature reviews. Drug discovery</i> 17 , 78 (2017). https://doi.org/10.1038/nrd.2017.267
077	55	Schwartz, D. M., Bonelli, M., Gadina, M. & O'Shea, J. J. Type I/II cytokines, JAKs, and new
078		strategies for treating autoimmune diseases. <i>Nature reviews. Rheumatology</i> 12 , 25-36 (2016).
079		https://doi.org:10.1038/nrrheum.2015.167
080	56	Maroun, L. E., Heffernan, T. N. & Hallam, D. M. Partial IFN-alpha/beta and IFN-gamma
081		receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron
082		viability. Journal of interferon & cytokine research: the official journal of the International
083		Society for Interferon and Cytokine Research 20, 197-203 (2000).
084		https://doi.org:10.1089/107999000312612
085	57	Bhattacharya, S., Cherry, C., Deutsch, G., Birth Defects Research Laboratory (BDRL), Glass,
086		I.A., Mariani, T.J., Al Alam, D., Danopoulos, S. A Trisomy 21 Lung Cell Atlas. bioRxiv doi:
087		https://doi.org/10.1101/2023.03.30.534839 (2023). https://doi.org/doi.
088		https://doi.org/10.1101/2023.03.30.534839
089	58	Aziz, N. M. et al. Lifespan analysis of brain development, gene expression and behavioral
090		phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome. Dis
091		Model Mech 11 (2018). https://doi.org:10.1242/dmm.031013

092 59 Rodero, M. P. & Crow, Y. J. Type I interferon-mediated monogenic autoinflammation: The type 093 I interferonopathies, a conceptual overview, The Journal of experimental medicine 213, 2527-094 2538 (2016). https://doi.org:10.1084/jem.20161596 095 60 Breslin, N. K., Varadarajan, V. V., Sobel, E. S. & Haberman, R. S. Autoimmune inner ear 096 disease: A systematic review of management. Laryngoscope Investig Otolaryngol 5, 1217-1226 097 (2020). https://doi.org:10.1002/lio2.508 098 61 Kocvigit, M. et al. Association Between Endocrine Diseases and Serous Otitis Media in 099 Children. J Clin Res Pediatr Endocrinol 9, 48-51 (2017). https://doi.org:10.4274/jcrpe.3585 100 62 Ercolini, A. M. & Miller, S. D. The role of infections in autoimmune disease. Clin Exp Immunol 101 155, 1-15 (2009). https://doi.org:10.1111/j.1365-2249.2008.03834.x 102 63 Dresser, L., Wlodarski, R., Rezania, K. & Soliven, B. Myasthenia Gravis: Epidemiology, 103 Pathophysiology and Clinical Manifestations. J Clin Med 10 (2021). 104 https://doi.org:10.3390/jcm10112235 105 64 Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H. & Gouda, A. M. A 106 Comprehensive Overview of Globally Approved JAK Inhibitors. *Pharmaceutics* **14** (2022). 107 https://doi.org:10.3390/pharmaceutics14051001 108 65 Ruperto, N. et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, 109 withdrawal phase 3 randomised trial. Lancet 398, 1984-1996 (2021). 110 https://doi.org:10.1016/S0140-6736(21)01255-1 111 King, B. A. & Craiglow, B. G. Janus kinase inhibitors for alopecia areata. *Journal of the* 66 112 American Academy of Dermatology 89, S29-S32 (2023). https://doi.org:10.1016/j.jaad.2023.05.049 113 114 67 Tampa, M., Mitran, C. I., Mitran, M. I. & Georgescu, S. R. A New Horizon for Atopic 115 Dermatitis Treatments: JAK Inhibitors. J Pers Med 13 (2023). 116 https://doi.org:10.3390/jpm13030384

117	68	Ytterberg, S. R. et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
118		The New England journal of medicine 386 , 316-326 (2022).
119		https://doi.org:10.1056/NEJMoa2109927
120	69	Santoro, J. D. et al. Assessment and Diagnosis of Down Syndrome Regression Disorder:
121		International Expert Consensus. Front Neurol 13, 940175 (2022).
122		https://doi.org:10.3389/fneur.2022.940175
123	70	Harris, P. A. et al. Research electronic data capture (REDCap)a metadata-driven methodology
124		and workflow process for providing translational research informatics support. J Biomed Inform
125		42 , 377-381 (2009). https://doi.org:10.1016/j.jbi.2008.08.010
126	71	Gu, Y. et al. High-throughput multiplexed autoantibody detection to screen type 1 diabetes and
127		multiple autoimmune diseases simultaneously. EBioMedicine 47, 365-372 (2019).
128		https://doi.org:10.1016/j.ebiom.2019.08.036
129	72	Finck, R. et al. Normalization of mass cytometry data with bead standards. Cytometry A 83, 483-
130		494 (2013). https://doi.org:10.1002/cyto.a.22271
131	73	Zunder, E. R. et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and
132		single-cell deconvolution algorithm. Nature protocols 10, 316-333 (2015).
133		https://doi.org:10.1038/nprot.2015.020
134	74	Hahne, F. et al. flowCore: a Bioconductor package for high throughput flow cytometry. BMC
135		bioinformatics 10, 106 (2009). https://doi.org:10.1186/1471-2105-10-106
136	75	Chevrier, S. et al. Compensation of Signal Spillover in Suspension and Imaging Mass
137		Cytometry. Cell Syst 6, 612-620 e615 (2018). https://doi.org:10.1016/j.cels.2018.02.010
138	76	Azad, A., Rajwa, B. & Pothen, A. flowVS: channel-specific variance stabilization in flow
139		cytometry. BMC Bioinformatics 17, 291 (2016). https://doi.org:10.1186/s12859-016-1083-9

140 77 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for 141 RNA-seq data with DESeq2. Genome biology 15, 550 (2014). https://doi.org:10.1186/s13059-142 014-0550-8 143 78 Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for 144 interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545-15550 145 (2005). https://doi.org:10.1073/pnas.0506580102 79 146 de Jesus, A. A. et al. Distinct interferon signatures and cytokine patterns define additional 147 systemic autoinflammatory diseases. The Journal of clinical investigation 130, 1669-1682 148 (2020). https://doi.org:10.1172/JCI129301 149 80 Banchereau, R. et al. Personalized Immunomonitoring Uncovers Molecular Networks that 150 Stratify Lupus Patients. Cell 165, 1548-1550 (2016). https://doi.org:10.1016/j.cell.2016.05.057 151 152

Article and author information.

Acknowledgements: This work was supported primarily by NIH grant R61AR077495. Additional funding was provided by NIH grants R01AI150305 (J.M.E.), T32CA190216 (K.A.W.), 2T32AR007411-31 (K.A.W.), UM1TR004399 (data generation and REDCap support), P30CA046934 (support of shared resources), the Linda Crnic Institute for Down Syndrome, the Global Down Syndrome Foundation, the Anna and John J. Sie Foundation, the Human Immunology and Immunotherapy Initiative, the University of Colorado School of Medicine, the Boettcher Foundation, and Fast Grants. We are grateful to all research participants and their families involved in the Human Trisome Project and the clinical trial. We thank Lyndy Bush for administrative support, Dr. Kim Jordan and her team at the Human Immune Monitoring Shared Resource for outstanding service in generation of the immune marker dataset, and Dr. Eric Clambey and his team at the Flow Cytometry Shared Resource for outstanding service in generation of the mass cytometry dataset. We are also grateful to the Colorado Translational and Sciences Institute and the Colorado Multiple Institutional Review Board for assistance in all clinical research projects involving the Crnic Institute. Special thanks to Michelle Sie Whitten, the team at the Global Down Syndrome Foundation, Dr. John Reilly, and Dr. Ron Sokol for logistical support at multiple stages of the project.

Author Contributions Statement: A.L.R.: conceptualization, methodology, formal analysis, project administration, data curation, visualization, investigation, resources, writing of manuscript; E.W.: methodology, data curation, investigation, writing of manuscript; E.G.: methodology, data curation, investigation, writing of manuscript; BEE: methodology, project administration, data curation, investigation, writing of manuscript; K.R.W.: methodology, data curation, investigation, writing of manuscript; K.P.S.: methodology, project administration, formal analysis, data curation, visualization, investigation, writing of manuscript; P.A.: conceptualization, methodology, formal analysis, data curation, visualization, investigation, investigation, writing of manuscript; K.A.W.: conceptualization, methodology,

investigation, writing of manuscript; R.E.G.: methodology, investigation, writing of manuscript; E.B.: methodology, investigation, writing of manuscript; H.R.L.: methodology, investigation, writing of manuscript; M.G.D.: methodology, investigation, formal analysis, data curation, visualization, writing of manuscript; N.P.E.: methodology, investigation, formal analysis, data curation, visualization, writing of manuscript; A.A.H.: conceptualization, methodology, project administration, investigation, writing of manuscript; B.M.: methodology, data curation, investigation, writing of manuscript; L.P.: methodology, investigation, formal analysis, data curation, project administration, writing of manuscript; D.F.: methodology, investigation, formal analysis, data curation, project administration, writing of manuscript; M.D.G.: methodology, investigation, formal analysis, data curation, visualization, project administration, writing of manuscript; C.A.D.: conceptualization, methodology, data curation, investigation, project administration, writing of manuscript; D.A.N.: conceptualization, methodology, data curation, investigation, resources, project administration, writing of manuscript; J.M.E.: conceptualization, methodology, project administration, visualization, investigation, resources, writing of manuscript.

- Competing Interests Statement: J.M.E. has provided consulting services for Eli Lilly Co., Gilead
- 193 Sciences Inc., and Biohaven Pharmaceuticals and serves on the advisory board of Perha Pharmaceuticals.
- 194 The remaining authors declare no competing interests.

196 Supplementary File Legends.

- 197 Supplementary file 1. (A) Cohort characteristics and (B) autoimmune conditions for Human Trisome
- 198 Project participants analyzed in this study.
- 199 Supplementary file 2. Autoantibody measurements of Human Tisome Project participants: (A) anti-
- 200 thyroid peroxidase (TPO) reactivity; (B) anti-nuclear antigen (ANA) reactivity; (C) SciLifeLabs
- autoantigen peptide array data.
- Supplementary file 3. (A) Minimum qualifying scores for skin conditions. (B) Cohort characteristics for
- 203 clinical trial participants.
- 204 **Supplementary file 4.** Adverse events for clinical trial participants.
- 205 Supplementary file 5. Skin pathology metrics for clinical trial participants: (A) Investigator's Global
- Assessment (IGA); (B) Dermatology Life Quality Index (DLQI); (C) Severity of Alopecia Tool (SALT);
- 207 (D) Psoriasis Area and Severity Index (PASI); and (E) Eczema Area and Severity Index (EASI).
- 208 Supplementary file 6. (A) DS IFN scores; (B) Cytokine scores; (C) anti-thyroid peroxidase (TPO) titers;
- 209 (D) anti-transglutaminase (TG) titers; and (E) anti-thyroid stimulating hormone receptor (TSHR) titers for
- 210 clinical trial participants.

213

214

- 211 **Supplementary file 7.** Marker information for mass cytometry analysis.
- 212 **Supplementary file 8.** Clinical trial protocol.